Endometrial cancer is the most common gynecologic cancer in the United States, diagnosed
in more than 50,000 women annually. While the majority of women present with low-grade …

Purpose Conventional platinum based chemotherapy for advanced urothelial carcinoma is
plagued by common resistance to this regimen. Several studies implicate the EGFR family of …

Resistance to endocrine therapies in hormone receptor (HR)-positive breast cancer is a
significant clinical problem for a considerable number of patients. The oncogenic …

Studies over the last two decades have identified that amplified human epidermal growth
factor receptor (HER‐2; c‐erbB‐2, neu) and its overexpression have been frequently …

Epidermal Growth Factor Receptor (EGFR) is an important target of anticancer therapy.
Nowadays, the search for new molecules inhibiting this receptor is turning toward natural …

Approximately 25% of breast cancers overexpress and depend on the receptor tyrosine
kinase ERBB2, one of 4 ERBB family members. Targeted therapies directed against ERBB2 …

Background Trastuzumab, a HER2 monoclonal antibody, has transformed the prognosis of
patients with the aggressive HER2-positive breast cancer type. Trastuzumab augments the …

Background The EGFR signaling pathway is frequently activated in human ovarian cancer
and associated with poor prognosis. However, inhibition of EGFR signaling in patients with …

The copper (I)-catalyzed 1, 3-dipolar cycloaddition between alkynes and azides (click
chemistry) to form 1, 2, 3-triazoles is the most popular reaction due to its reliability …

Although EGFR is a validated therapeutic target across multiple cancer indications, the often
modest clinical responses to current anti-EGFR agents suggest the need for improved …